Overlapping area represents amount of risk that can be diversified away by holding Biovail Corp. Common Stoc and Alkermes Inc. in the same portfolio (assuming nothing else is changed)
Valeant Pharmaceuticals International, Inc. raised bidding price from $6.50 to $7.50 per share in cash relevant to its earlier proposed price for the acquisition of ISTA Pharmaceuticals.
Boston-based Hambrecht & Quist Capital Management (HQCM), led by CEO & portfolio manager Daniel Omstead, and with over $475 million in 13-F assets per its latest Q4 filing on Friday, is the registered investment adviser to two closed-end equity funds, ...
DUBLIN--(BUSINESS WIRE)--Feb. 6, 2012-- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012, at 2:30 pm EST (7:30 pm GMT) from ...
DUBLIN, Feb 06, 2012 (BUSINESS WIRE) -- Alkermes plc /quotes/zigman/6688932/quotes/nls/alks ALKS -2.13% announced today that its corporate presentation will be webcast live at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012, ...
Novo Nordisk (NVO) reported earnings of $1.51 per American Depository Receipt (ADR), in the fourth quarter 2011, much above the Zacks Consensus Estimate of $1.24.
2012-02-06
Novo Nordisk Posts Solid 4Q
2012-02-06
The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company
2012-02-06
Revenues Skyrocket at Merged Alkermes
2012-02-03
Updating Transaction...
Click "OK" to permanently delete this portfolio. Click "Cancel" if you have changed your mind.
USA 
Select Assests
Optimize Portfolio
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatilities
Import Equities
Search Equities
Filter Tops
Biovail Corp. Common Stoc and 
Alkermes Inc.
Alkermes Inc.
1.83% 
